


PHARMACEUTICAL 2017


Blueprint Medicines Corp Rank 31 of 292







PHARMACEUTICAL 2017





The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Blueprint Medicines Corp is the variable Research and Development, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 231% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	220,425
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,512
Liabilities, Non-Current	0
Other Assets	56,182
Other Compr. Net Income	-18
Other Expenses	0
Other Liabilities	0
Other Net Income	82
Other Revenues	27,772
Property and Equipment	6,188
Research and Development	81,131
Selling, General and Administrative Expense	19,218

Output Variable	Value in 1000 USD
Assets	282,795
Liabilities	28,512
Expenses	100,349
Revenues	27,772
Stockholders Equity	254,283
Net Income	-72,495
Comprehensive Net Income	-72,504
Economic Capital Ratio	234%

